https://www.pharmaradar360.com/article/d09308d7df524923Pharma Surgeen2026-06-03T11:05:00.000ZMedtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United Stateshttps://www.pharmaradar360.com/article/55cffcffda0b58f9Pharma Surgeen2026-06-03T10:55:00.000ZMedtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadenshttps://www.pharmaradar360.com/article/7f92b11714342011Pharma Surgeen2026-06-03T10:45:00.000ZMedtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 yearshttps://www.pharmaradar360.com/article/3040ff43de8651e4Pharma Surgeen2026-06-03T10:43:39.000ZMedicine levy makes the UK un-investable, say pharma leadershttps://www.pharmaradar360.com/article/51547deb486afaa2Pharma Surgeen2026-06-03T09:14:16.000ZContactpunt afdeling Geneesmiddelen voor Diergeneeskundig Gebruikhttps://www.pharmaradar360.com/article/3ba425f9fe852f55Pharma Surgeen2026-06-03T08:19:34.000ZChoosing the hardest problems: why Ipsen focuses where unmet need is greatesthttps://www.pharmaradar360.com/article/0d81eb7953e1c9a8Pharma Surgeen2026-06-03T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/698094b3687fb094Pharma Surgeen2026-06-03T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/19fd9d6c84f84bf1Pharma Surgeen2026-06-03T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/92353aba467913f5Pharma Surgeen2026-06-03T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/123ded968816706aPharma Surgeen2026-06-03T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/bc8fc8b5602c9bbePharma Surgeen2026-06-03T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/90c8497ae7a06d04Pharma Surgeen2026-06-03T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/49fd29ab82f1d983Pharma Surgeen2026-06-03T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/5c798da7553ea629Pharma Surgeen2026-06-03T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/bc0464f49b8da643Pharma Surgeen2026-06-03T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/f70e37fbdf02b32ePharma Surgeen2026-06-03T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/16dd72f1b20d780bPharma Surgeen2026-06-03T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/accdf1021877daf9Pharma Surgeen2026-06-03T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/835be8404965dcfdPharma Surgeen2026-06-03T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/6380fca3a3c41b3bPharma Surgeen2026-06-02T16:49:02.000ZThree steps to boost patient access to clinical trials in the UKhttps://www.pharmaradar360.com/article/98b0f00cbb256d60Pharma Surgeen2026-06-02T16:44:16.000ZUnderstanding medicine shortages and how we’re working to avoid themhttps://www.pharmaradar360.com/article/7da544e65caaaa6fPharma Surgeen2026-06-02T16:40:41.000ZEquity in the age of advanced therapies: insights from haemophiliahttps://www.pharmaradar360.com/article/9d42e0806e04ac55Pharma Surgeen2026-06-02T16:37:31.000ZGrowth and skills levy: A catalyst for the UK pharmaceutical industry?https://www.pharmaradar360.com/article/2e19ec3b3bd53f19Pharma Surgeen2026-06-02T16:21:04.000ZABPI refreshes its commitment to improve public involvement in researchhttps://www.pharmaradar360.com/article/ccb605e47bb11442Pharma Surgeen2026-06-02T16:19:48.000ZSetor farmacêutico está entre os principais depositantes de patentes no Brasil, segundo ranking do INPIhttps://www.pharmaradar360.com/article/1b1193819c31653bPharma Surgeen2026-06-02T16:19:05.000ZWorking together, we are all determined to create more medicines for pregnant womenhttps://www.pharmaradar360.com/article/a0fc0ad5110af229Pharma Surgeen2026-06-02T16:15:05.000ZABPI statement on BGMA legal action over Voluntary Scheme negotiation representationhttps://www.pharmaradar360.com/article/82638378be61c046Pharma Surgeen2026-06-02T16:00:00.000ZBMS-Hengrui deal strikes panic in Washingtonhttps://www.pharmaradar360.com/article/80e9f89818553695Pharma Surgeen2026-06-02T16:00:00.000ZChina launches long-awaited drug data protection ruleshttps://www.pharmaradar360.com/article/2321df2a7beb0435Pharma Surgeen2026-06-02T16:00:00.000ZLongbio to raise HK$1.4B in Hong Kong IPO for immunology workhttps://www.pharmaradar360.com/article/2e8e71442973380aPharma Surgeen2026-06-02T16:00:00.000ZChina deals highlight biopharma evolution, reports LEKhttps://www.pharmaradar360.com/article/ce87182366906693Pharma Surgeen2026-06-02T15:54:20.000ZNHS-industry partnerships can support the NHS to make the government’s three big shiftshttps://www.pharmaradar360.com/article/f7f1f7360844be4cPharma Surgeen2026-06-02T15:46:30.000ZEquitable access to medicines and vaccines essential for patient safety and outcomes, says ABPIhttps://www.pharmaradar360.com/article/957c19b7c16940d6Pharma Surgeen2026-06-02T15:43:43.000ZInnovation with integrity: Why NHS-industry partnerships matter, and how conflicts of interest are managedhttps://www.pharmaradar360.com/article/4f560f7af73b7df0Pharma Surgeen2026-06-02T15:39:33.000ZFirst of its kind coalition sees health industry, professional bodies and experts come together to holistically tackle ‘hidden pandemic’ of antibiotic resistant infectionshttps://www.pharmaradar360.com/article/e564b3eb6b9d09ffPharma Surgeen2026-06-02T15:04:04.000ZLatest Disclosure UK data: higher R&D spend, greater transparency and more partnership with the NHShttps://www.pharmaradar360.com/article/fbc4cf3aca0b2cc2Pharma Surgeen2026-06-02T15:02:58.000ZWhen Regulators Use AI: What It Means for MedTech Teamshttps://www.pharmaradar360.com/article/d570667073ef265aPharma Surgeen2026-06-02T13:30:00.000ZLilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meetinghttps://www.pharmaradar360.com/article/2686ddd0400a6989Pharma Surgeen2026-06-02T13:09:11.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/68c7a5377bbff33aPharma Surgeen2026-06-02T13:04:51.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/11c16dfad4c4d332Pharma Surgeen2026-06-02T13:04:38.000ZClass 2 Medicines Recall: Becton Dickinson UK Ltd, ChloraPrep 2% 1mL and ChloraPrep Frepp 2% 1.5mL applicators, EL(26)A/26https://www.pharmaradar360.com/article/b7ce2af2fe2e1964Pharma Surgeen2026-06-02T12:42:55.000ZDecision: Human medicines: register of electronic export certificateshttps://www.pharmaradar360.com/article/246b52a85c4281ecPharma Surgeen2026-06-02T12:00:00.000ZAbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conferencehttps://www.pharmaradar360.com/article/9b9b225d3f738affPharma Surgeen2026-06-02T12:00:00.000ZIzalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinomahttps://www.pharmaradar360.com/article/2584be305d0c5f74Pharma Surgeen2026-06-02T11:17:24.000ZΑνάκληση παρτίδας του προϊόντος «Γάζα απλή 10X10-12ply»https://www.pharmaradar360.com/article/8e65ea502349fd78Pharma Surgeen2026-06-02T10:52:05.000ZField Safety Notices: 25 to 29 May 2026https://www.pharmaradar360.com/article/ea136623f08d2718Pharma Surgeen2026-06-02T10:49:22.000ZLa AEMPS presenta los principales hitos de 2025 en su Memoria de Actividadeshttps://www.pharmaradar360.com/article/8df7ad55f69dc4e8Pharma Surgeen2026-06-02T10:45:00.000ZMerck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conferencehttps://www.pharmaradar360.com/article/6319a26ea2a5eb86Pharma Surgeen2026-06-02T10:38:37.000ZLa AEMPS informa del cese de comercialización y retirada del mercado del dispositivo antiatragantamientos DAEMhttps://www.pharmaradar360.com/article/1792a56b7ff75d7ePharma Surgeen2026-06-02T09:31:54.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος, CRE Wireguided Balloon Dilatation Catheter CRE PRO και CRE PRO GI (Καθετήρες διαστολής με μπαλόνι)https://www.pharmaradar360.com/article/14c872821cf15ddcPharma Surgeen2026-06-02T08:25:58.000ZNAFDAC Launches Improved Med Safety App to Strengthen Reporting of Substandard and Falsified Medical Products and Adverse Drug Reactions in Nigeriahttps://www.pharmaradar360.com/article/71236effdcf9c013Pharma Surgeen2026-06-02T08:00:00.000ZAbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adultshttps://www.pharmaradar360.com/article/e1942947ccb968aePharma Surgeen2026-06-02T05:32:47.000ZStavros Nicolaou honoured with Lifetime Leadership Awardhttps://www.pharmaradar360.com/article/29e0285efa209b8bPharma Surgeen2026-06-02T05:00:00.000ZFDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative settinghttps://www.pharmaradar360.com/article/8c7a2fb9a250e796Pharma Surgeen2026-06-02T00:00:00.000ZHow to Get Rid of Pesky Mosquitoeshttps://www.pharmaradar360.com/article/7bd49f74f64a6e08Pharma Surgeen2026-06-02T00:00:00.000ZSputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Onlinehttps://www.pharmaradar360.com/article/40df6d619efe51abPharma Surgeen2026-06-01T22:00:00.000ZResultados financieros del primer semestre de 2026